TSTickerStar
Company alerts/ALMS
ALMS company alerts

ALMS updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for ALMS. Subscribe to ALMS alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent ALMS alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

EarningsOfficial company source

Alumis Reports Q3 2026 Financial Results; LUMUS Phase 2b Trial in SLE Missed Primary Endpoint in Overall Population

Alumis reported Q3 2026 net loss of $94.9 million versus net loss of $110.8 million in Q3 2025, as R&D expenses declined to $80.8 million from $97.8 million. Revenue was $1.9 million, down slightly from $2.1 million in the prior-year quarter. The Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) did not meet primary or secondary endpoints in the overall trial population, though robust clinical responses were observed in a prespecified subgroup of patients with high interferon gene sig...

Read source-backed brief
SEC filingSEC filing

ALMS 10-Q filed 2026-11-12 | Key takeaways

ALMS filed its 10-Q; the most relevant disclosure change is expanded Going concern disclosure: The company states that its existing cash, cash equivalents and marketable securities of $431.3 million as of September 30, 2026 will not be sufficient to meet its operating and capital requirements for at least 12 months from the date of issuance of the finan. Customer concentration: Kaken Pharmaceutical Co., Ltd. represented 100% of revenue.

Read source-backed brief